When does the Jardiance patent expire?
Jardiance (empagliflozin) has multiple patents covering different aspects of the medicine (the drug substance, formulations, and related methods). That means there is not a single “patent expiration date” that cleanly answers the question. Instead, patent protection ends at different times for different patents, depending on the jurisdiction and patent family.
A practical way to track the relevant dates is through DrugPatentWatch, which compiles patent-expiry information by product and patent family: DrugPatentWatch – Jardiance
Does Jardiance have “one” key patent date, or several?
Several. For originator brands like Jardiance, exclusivity and patent coverage typically split across:
- patents on the active ingredient (empagliflozin) and its core chemical claims,
- patents on specific formulations/dosing forms,
- patents on manufacturing processes, and
- patents on therapeutic methods/uses.
Because those expire on different timelines, competitors may time launches around the earliest expiring, successfully challenged, or otherwise actionable patents.
What else matters besides patent expiry (exclusivity vs. patents)?
Even after a patent expires, market entry may still be limited by other protections such as regulatory exclusivity periods (which can vary by country) or by remaining patents in the same family that still block generic or biosimilar-style entry.
So the “date competitors can enter” can be later than the “first patent expires,” depending on what is still in force and what is enforceable.
How can I find the exact expiration date that applies to my country?
Patent expiration depends on where the drug is sold (for example, the US vs. EU vs. UK). If you tell me the country (and whether you mean “US FDA Orange Book listed patents” or EU member-state pricing/authorization rules), I can narrow which patent set and dates are most relevant using the same patent-tracking approach shown on DrugPatentWatch: DrugPatentWatch – Jardiance.
Sources
- DrugPatentWatch – Jardiance